Deals In Depth: June/July 2013

Article preview from IN VIVO - September, 2013

In a regional deal, AstraZeneca licensed rights to FibroGen’s renal candidate in an alliance worth $815 million; Elan finally agreed to an $8.3 billion takeover by Perrigo; biopharma financing totaled $7.1 billion and $2 billion in June and July, respectively, while device fundraising reached $325 million and $316 million in the same months.

Deals In Depth: June/July 2013 

Article preview from IN VIVO - September, 2013

Our monthly overview of dealmaking in the biopharma, device, and diagnostics industries.

 In a regional deal, AstraZeneca licensed rights to FibroGen’s renal candidate for $350 million up front and $465 million in development milestones.

After months of fighting off a bid from Royalty Pharma, Elan finally agreed to an $8.3 billion acquisition by Perrigo. One Equity Partners sold Systagenix Wound Management to Kinetic Concepts for $485 million.

Biopharma financing totaled $7.1 billion and $2 billion in June and July, respectively; June’s numbers were boosted by Valeant’s large debt and equity offerings. Device fundraising reached $325 million and $316 million in June and July, respectively; the largest transaction was insulin device maker Valeritas’ $100 million debt financing from Capital Royalty.

Continued...

Purchase this article online as a PDF and receive it immediately via email. Questions? Call (800) 332-2181. 100% Satisfaction Guaranteed.

Plus:
To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985-9512